FAS and cancer: This work was funded by ‘Systems Biology of Signalling in Cancer (SBCancer)', part of the Helmholtz Alliance on Systems Biology and Interdisziplinäres Forschungsprogramm des Nationalen Centrums für Tumorerkrankungen (NCT)-Heidelberg (Grant Title: ‘Hemmung des CD95 Signalweges als neuer therapeutischer Ansatz zur Behandlung des duktalen Pankreasadenokarzinoms (PDAC)'), the German Cancer Research Centre (DKFZ), the German Cancer Consortium (Deutsches Konsortium für Translationale Krebsforschung; DKTK) and the Helmholtz Alliance of Preclinical Comprehensive Cancer Center (PCCC).